Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

No adjuvant therapy has been shown to extend the survival of patients with hepatocellular carcinoma (HCC) receiving curative treatment. We investigated whether injections of activated cytokine-induced killer (CIK) cells (CD3+/CD56+ and CD3+/CD56- T cells and CD3-/CD56+ natural killer cells) prolongs recurrence-free survival of patients after curative therapy for HCC.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Gastroenterology

Title: Gastroenterology

ISSN (Electronic): 1528-0012

ISSN (Print): 0016-5085

Publication date (Electronic): Jun 2015

Volume: 148

Issue: 7

Affiliations

[1 ] Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

[2 ] Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.

[3 ] Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

[4 ] The Liver Center, Korea University Guro Hospital, Seoul, Korea.

[5 ] Department of Surgery, Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea.

[6 ] Department of Statistics, Korea University, Seoul, Korea.

[7 ] Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. Electronic address: yoonjh@snu.ac.kr.

Article

Publisher Item ID: S0016-5085(15)00305-4

DOI: 10.1053/j.gastro.2015.02.055

PubMed ID: 25747273

SO-VID: 0f958971-34e3-4e5e-8848-b9c0da84038c

Keywords: Clinical Trial,IL2,Liver Cancer,NK Cell

Data availability:

Keywords: Clinical Trial, IL2, Liver Cancer, NK Cell

Comments

Comment on this article

Cited by 168

See all cited by